Compare KraneShares CSI China Internet ETF (KWEB) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares CSI China Internet ETF vs Zimmer Biomet Holdings Inc — how do they compare? KraneShares CSI China Internet ETF trades at $24.93 (market cap $4.37B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 3.9× KraneShares CSI China Internet ETF's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while KraneShares CSI China Internet ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold KraneShares CSI China Internet ETF for 57 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| KWEB | ZBH | |
|---|---|---|
Market Cap | $4.37B | $16.95B |
Volume | 13,393,361 | 2,505,240 |
Sector | Sector/Thematic | Health |
52-Week High | $41.35 | $103.98 |
52-Week Low | $23.63 | $79.58 |
Typical Hold Time | 57 Days | 89 Days |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KWEB trades at $24.025, down 1.25% on the day, with a bearish technical outlook showing 18 sell signals versus 0 buy signals across indicators. The ETF faces headwinds from China's economic challenges including industrial overcapacity and weak domestic consumption. Recent institutional activity shows mixed positioning with Tidal Investments reducing its stake by 39.1% while HSBC Holdings increased its position by 27.7% in recent quarters.
The outlook remains cautious given China's economic pressures and U.S.-China trade tensions, though potential tariff reductions from the Trump-Xi summit could provide catalysts. Key risks include rising global protectionism against Chinese exports and China's persistent economic rebalancing challenges. The neutral RSI readings suggest potential for consolidation near current levels.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% on the day, with a bearish technical signal but strong recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and maintains a solid gross profit margin of 69.87%. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated. Analyst consensus is a 'Buy' with a $103.11 price target, indicating potential upside from current levels.
The outlook for ZBH is cautiously optimistic, supported by earnings momentum and a diversified medical technology portfolio. Key risks include rising debt levels, with debt-to-asset ratio increasing to 32.57% in 2025, and competitive pressures in the healthcare sector. Institutional ownership trends show continued interest, but investors should monitor margin sustainability and capital expenditure efficiency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KraneShares CSI China Internet ETF
KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.
Read more on KWEB →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
